Hsbc Holdings PLC Legend Biotech Corp Transaction History

Hsbc Holdings PLC

$145 Billion
Q1 2024

A detailed history of Hsbc Holdings PLC transactions in Legend Biotech Corp stock. As of the latest transaction made, Hsbc Holdings PLC holds 211,650 shares of LEGN stock, worth $9.47 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

211,650

Previous 196,715 7.59%

Holding current value

$9.47 Million

Previous $11.8 Million 0.3%

% of portfolio

0.01%

Previous 0.01%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$55.06 - $69.99 $822,321 - $1.05 Million	14,935 Added 7.59%	211,650 $11.9 Million
Q4 2023 Feb 12, 2024	BUY	$57.25 - $69.74 $6.18 Million - $7.53 Million	107,991 Added 121.72%	196,715 $11.8 Million
Q3 2023 Nov 13, 2023	SELL	$63.16 - $76.5 $6.28 Million - $7.61 Million	-99,486 Reduced 52.86%	88,724 $5.96 Million
Q2 2023 Aug 11, 2023	BUY	$46.28 - $75.01 $3.3 Million - $5.35 Million	71,317 Added 61.01%	188,210 $13 Million
Q1 2023 May 15, 2023	BUY	$43.42 - $57.37 $1.94 Million - $2.57 Million	44,767 Added 62.07%	116,893 $5.64 Million

Q4 2022 Feb 14, 2023	BUY	$38.8 - $55.46 $475,920 - $680,272	12,266 Added 20.49%	72,126 $3.6 Million
Q3 2022 Nov 14, 2022	BUY	$38.15 - $57.1 $208,375 - $311,880	5,462 Added 10.04%	59,860 $2.44 Million
Q2 2022 Aug 11, 2022	BUY	$33.54 - $55.0 $237,865 - $390,060	7,092 Added 14.99%	54,398 $2.99 Million
Q1 2022 May 16, 2022	BUY	$31.02 - $48.18 $476,250 - $739,707	15,353 Added 48.05%	47,306 $1.72 Million
Q4 2021 Feb 11, 2022	BUY	$41.14 - $56.98 $1.31 Million - $1.82 Million	31,953 New	31,953 $1.49 Million

Others Institutions Holding LEGN

# of Institutions

213

Shares Held

63.6M

Call Options Held

1.09M

Put Options Held

525K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $7.49B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Hsbc Holdings PLC with notifications on news.

Account

Hsbc Holdings PLC Legend Biotech Corp Transaction History